OX40L Human
Description
OX40L Human Recombinant is a single, glycosylated, polypeptide chain (51-183 a.a) containing a total of139 amino acids and having a molecular mass of 16.2 kDa.
OX40L is fused to a 6 a.a his-Tag at C-terminus and is purified by proprietary chromatographic techniques.
Product Specs
Tumor necrosis factor ligand superfamily member 4, OX40 ligand, OX40L, OX-40L, CD252, Tnfsf4, Ox40l, Txgp1l, gp3, OX4, Ath-1, Ath1, CD134L, gp34, Tnlg2b, Txgp1l.
HEK293 Cells.
QVSHRYPRIQ SIKVQFTEYK KEKGFILTSQ KEDEIMKVQN NSVIINCDGF YLISLKGYFS QEVNISLHYQ KDEEPLFQLK KVRSVNSLMV ASLTYKDKVY LNVTTDNTSL DDFHVNGGEL ILIHQNPGEF CVLHHHHHH.
Product Science Overview
OX40 Ligand, also known as tumor necrosis factor ligand superfamily member 4 (TNFSF4), is a type II transmembrane glycoprotein. It is a member of the tumor necrosis factor (TNF) superfamily and is also referred to as CD252. The ligand is primarily expressed on the surface of antigen-presenting cells such as dendritic cells, macrophages, and activated B lymphocytes .
The human OX40 Ligand cDNA encodes a polypeptide consisting of 183 amino acids. This polypeptide includes an amino-terminal cytoplasmic domain and a carboxy-terminal extracellular domain . The OX40 Ligand interacts with its receptor, OX40 (also known as CD134 or TNFRSF4), which is present on the surface of activated T lymphocytes, natural killer (NK) cells, NKT cells, and neutrophils .
The binding of OX40 Ligand to OX40 provides a survival signal for T cells and facilitates the development of memory T cells. This interaction also promotes the polarization of the immune response towards a Th2 phenotype, even in environments with low levels of interleukin-4 (IL-4) cytokine .
Recombinant human OX40 Ligand is typically produced using mammalian cell lines, such as the mouse myeloma cell line NS0. The recombinant protein is purified to a high degree, often exceeding 95% purity as determined by SDS-PAGE under reducing conditions . The protein is supplied as a filtered solution in phosphate-buffered saline (PBS) and is available in both carrier-free and carrier-containing formulations .
The bioactivity of recombinant human OX40 Ligand is measured by its ability to induce interleukin-8 (IL-8) secretion in human fibrosarcoma cells transfected with human OX40. The effective dose (ED50) for this activity is typically in the range of 1-5 ng/mL . Additionally, the binding ability of OX40 Ligand is assessed using functional ELISA, where the ligand’s concentration required for 50% optimal binding response is approximately 0.5-3 ng/mL .
The expression of OX40 Ligand on the surface of cells is regulated by various pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and prostaglandin E2 (PGE2) . These mediators induce the surface expression of OX40 Ligand on non-immune cells such as endothelial cells and smooth muscle cells .
